跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
IMJUDO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
IMJUDO
Authorized
STANDARD
IMJUDO
astrazeneca canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
679dca61925133b9
Company
astrazeneca canada inc
Type
Standard
Approval Details
Approval Id
679dca61925133b9
Drug Approval Canada Name
IMJUDO
Product Name
IMJUDO
Status
Marketed
Status Date
2023-10-23
Original Market Date
2023-10-23
Din
02541009
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01FX20 TREMELIMUMAB
Atc Name
l 01 fx 20
Aig Number
0164941001
Company Name
astrazeneca canada inc
Company Address
1004 Middlegate Road, Suite 5000, Mississauga, Ontario, Canada, L4Y 1M4
Active Ingredients
TREMELIMUMAB
20 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
679dca61925133b9
Type
Standard
Back to Health Canada Approvals